Abstract
Considerable progress has been made in the understanding of the molecular structure and mechanistic aspects of Angiostatin and Endostatin, endogenous angiogenesis inhibitors that have been shown to regress tumors in murine models. The growing body of literature surrounding these molecules and on the efficacy of these proteins is in part due to the ability to generate these proteins in recombinant systems as well characterized molecules. Recombinant human Angiostatin and Endostatin are in Phase I trials, following the manufacture of clinical grade material at large scale. This review highlights the recent advances made on understanding the structure and function of Angiostatin and Endostatin.
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Angiogenesis Inhibitors / toxicity
-
Angiostatins
-
Animals
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Agents / toxicity
-
Clinical Trials as Topic
-
Collagen / physiology*
-
Collagen / therapeutic use*
-
Collagen / toxicity
-
Endostatins
-
Humans
-
Neoplasms / blood supply
-
Neoplasms / drug therapy*
-
Neoplasms / pathology
-
Neoplasms, Experimental / blood supply
-
Neoplasms, Experimental / drug therapy
-
Neoplasms, Experimental / pathology
-
Peptide Fragments / physiology*
-
Peptide Fragments / therapeutic use*
-
Peptide Fragments / toxicity
-
Plasminogen / physiology*
-
Plasminogen / therapeutic use*
-
Plasminogen / toxicity
-
Recombinant Proteins / therapeutic use
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Endostatins
-
Peptide Fragments
-
Recombinant Proteins
-
Angiostatins
-
Plasminogen
-
Collagen